BG
ABBV icon

Benedetti & Gucer’s AbbVie ABBV Stock Holding History

Benedetti & Gucer’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$267K Buy
+1,464
New +$252K 0.13% 118

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Benedetti & Gucer's ABBV Position: Q1 2024 in Review

Benedetti & Gucer opened a new position in AbbVie (ABBV) in Q1 2024: 1,464 shares worth $267K. The stake represents 0.13% of the portfolio and ranks #118 among its holdings.

3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • Benedetti & Gucer held 1,464 shares of AbbVie worth $267K as of Q1 2024.
  • AbbVie was a new Benedetti & Gucer position in Q1 2024.
  • AbbVie made up 0.13% of Benedetti & Gucer's portfolio in Q1 2024, its #118 holding.
  • 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Benedetti & Gucer's 13F filing for Q1 2024, filed 7 May 2024.